Cargando…

1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021

BACKGROUND: The study aims to evaluate the in vitro activity of ceftolozane/tazobactam (C/T) and other common-used antibiotics against clinical Gram-negative bacterial (GNB) isolates obtained from Chinese pediatric patients using data from The Study for Monitoring Antimicrobial Resistance Trends (SM...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xinli, Fu, Ying, Li, Pengcheng, Yu, Yunsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679302/
http://dx.doi.org/10.1093/ofid/ofad500.1531
_version_ 1785150563767287808
author Mu, Xinli
Fu, Ying
Li, Pengcheng
Yu, Yunsong
author_facet Mu, Xinli
Fu, Ying
Li, Pengcheng
Yu, Yunsong
author_sort Mu, Xinli
collection PubMed
description BACKGROUND: The study aims to evaluate the in vitro activity of ceftolozane/tazobactam (C/T) and other common-used antibiotics against clinical Gram-negative bacterial (GNB) isolates obtained from Chinese pediatric patients using data from The Study for Monitoring Antimicrobial Resistance Trends (SMART). METHODS: From 2017-2021, 554 Gram-negative isolates were collected from 16 pediatric departments across China. GNB isolates from pediatric departments were mainly derived from bloodstream (n = 135), intraperitoneal (n = 129), lower respiratory tract (n = 198) and urinary tract (n = 92) infections (Figure 1). The minimum inhibitory concentrations (MICs) were tested using a Trek Diagnostic System (Thermo Fisher Scientific). Susceptibility was determined by CLSI broth microdilution and interpreted with CLSI M100 (2021) breakpoints. [Figure: see text] RESULTS: E. coli (34.30%) and K. pneumoniae (27.62%) were the most common pathogens, followed by P. aeruginosa (15.34%). Susceptibility of species with more than 20 isolates were showed in Table 1. The susceptibility of P. aeruginosa to C/T was 89.41%, which was the highest among beta-lactams and was second only to amikacin. The susceptibilities of E. coli and K. pneumoniae isolates to C/T were 92.63% and 58.17%, respectively. When exclude carbapenem-resistant E. coli and K. pneumoniae, the susceptibility to C/T increased to 96.17% and 86.14%. C/T showed similar activities to E. coli and K. pneumoniae isolated from pediatric patients < 1 year (Table 2). Thirteen P. aeruginosa isolates were collected from patients < 1 year and 13/13 were susceptible to C/T (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: P. aeruginosa and E. coli obtained from pediatric patients in China showed a high susceptibility to C/T. When excluding carbapenem resistant isolates, C/T also showed good activities against K. pneumoniae. DISCLOSURES: Pengcheng Li, M.D., MSD China: Employee of MSD China
format Online
Article
Text
id pubmed-10679302
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106793022023-11-27 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021 Mu, Xinli Fu, Ying Li, Pengcheng Yu, Yunsong Open Forum Infect Dis Abstract BACKGROUND: The study aims to evaluate the in vitro activity of ceftolozane/tazobactam (C/T) and other common-used antibiotics against clinical Gram-negative bacterial (GNB) isolates obtained from Chinese pediatric patients using data from The Study for Monitoring Antimicrobial Resistance Trends (SMART). METHODS: From 2017-2021, 554 Gram-negative isolates were collected from 16 pediatric departments across China. GNB isolates from pediatric departments were mainly derived from bloodstream (n = 135), intraperitoneal (n = 129), lower respiratory tract (n = 198) and urinary tract (n = 92) infections (Figure 1). The minimum inhibitory concentrations (MICs) were tested using a Trek Diagnostic System (Thermo Fisher Scientific). Susceptibility was determined by CLSI broth microdilution and interpreted with CLSI M100 (2021) breakpoints. [Figure: see text] RESULTS: E. coli (34.30%) and K. pneumoniae (27.62%) were the most common pathogens, followed by P. aeruginosa (15.34%). Susceptibility of species with more than 20 isolates were showed in Table 1. The susceptibility of P. aeruginosa to C/T was 89.41%, which was the highest among beta-lactams and was second only to amikacin. The susceptibilities of E. coli and K. pneumoniae isolates to C/T were 92.63% and 58.17%, respectively. When exclude carbapenem-resistant E. coli and K. pneumoniae, the susceptibility to C/T increased to 96.17% and 86.14%. C/T showed similar activities to E. coli and K. pneumoniae isolated from pediatric patients < 1 year (Table 2). Thirteen P. aeruginosa isolates were collected from patients < 1 year and 13/13 were susceptible to C/T (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: P. aeruginosa and E. coli obtained from pediatric patients in China showed a high susceptibility to C/T. When excluding carbapenem resistant isolates, C/T also showed good activities against K. pneumoniae. DISCLOSURES: Pengcheng Li, M.D., MSD China: Employee of MSD China Oxford University Press 2023-11-27 /pmc/articles/PMC10679302/ http://dx.doi.org/10.1093/ofid/ofad500.1531 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Mu, Xinli
Fu, Ying
Li, Pengcheng
Yu, Yunsong
1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title_full 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title_fullStr 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title_full_unstemmed 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title_short 1698. Activity of ceftolozane/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021
title_sort 1698. activity of ceftolozane/tazobactam in vitro against gram-negative isolates from pediatric patients: smart 2017-2021
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679302/
http://dx.doi.org/10.1093/ofid/ofad500.1531
work_keys_str_mv AT muxinli 1698activityofceftolozanetazobactaminvitroagainstgramnegativeisolatesfrompediatricpatientssmart20172021
AT fuying 1698activityofceftolozanetazobactaminvitroagainstgramnegativeisolatesfrompediatricpatientssmart20172021
AT lipengcheng 1698activityofceftolozanetazobactaminvitroagainstgramnegativeisolatesfrompediatricpatientssmart20172021
AT yuyunsong 1698activityofceftolozanetazobactaminvitroagainstgramnegativeisolatesfrompediatricpatientssmart20172021